Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 305 participants.

Also called NCT07102628

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 305 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07102628
  • EudraCT 2025-521670-34
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, Canada, China, France, Germany, Hong Kong SAR China, Hungary, India, Japan, Poland, South Korea, Spain, Switzerland (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07102628. Randomized; quadruple masking; primary purpose treatment. Start 2025-10-03 (actual); primary completion 2027-01-16 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
Acronym
ACS
Condition
Acute Coronary Syndrome
Intervention (Drug)
Placebo
Intervention (Drug)
Inclisiran
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07102628
Content hash
b59bb8c6be8d8ce174ea0ceaf49f86d8ef3122b42834212701f57c3276d67366